Q-omics provides the consensus-scored FOXO3 profile across patient tissues and cancer cell-line models. FOXO3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FOXO3 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, FOXO3 RNA expression shows 19,909 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where FOXO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXO3 survival associations across molecular data types. FOXO3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXO3 RNA expression–survival associations across cancer types. High FOXO3 expression shows unfavorable associations in BLCA and LIHC, but favorable associations in KIRC, UVM, SKCM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FOXO3 RNA expression.
This table summarizes FOXO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FOXO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXO3 shows lower tumor expression in KICH, THCA, LUAD and UCEC and higher tumor expression in HNSC and KIRC. The KICH box plot shows higher FOXO3 RNA expression in normal versus tumor tissue (log2 FC = −1.294, t-test p < 0.001).
This table shows molecular features associated with FOXO3 in patient tissues and cancer cell lines. In patient samples, FOXO3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
